REVIEW article

Front. Oncol., 31 January 2023

Sec. Molecular and Cellular Oncology

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1078768

Notch signaling, hypoxia, and cancer

  • 1. Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 2. Key Laboratory of Pulmonary Diseases of National Health Commission, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, China

Article metrics

View details

45

Citations

5k

Views

2,4k

Downloads

Abstract

Notch signaling is involved in cell fate determination and deregulated in human solid tumors. Hypoxia is an important feature in many solid tumors, which activates hypoxia-induced factors (HIFs) and their downstream targets to promote tumorigenesis and cancer development. Recently, HIFs have been shown to trigger the Notch signaling pathway in a variety of organisms and tissues. In this review, we focus on the pro- and anti-tumorigenic functions of Notch signaling and discuss the crosstalk between Notch signaling and cellular hypoxic response in cancer pathogenesis, including epithelia-mesenchymal transition, angiogenesis, and the maintenance of cancer stem cells. The pharmacological strategies targeting Notch signaling and hypoxia in cancer are also discussed in this review.

1 Introduction

The discovery of Notch signaling dates back to the early 1900s when a specific Drosophila wing phenotype showed notches on the wings which resulted from the mutations in the Notch receptor. Meanwhile, several other mutations have also been identified, such as Delta and Serrate, which similarly turned out to reside in genes encoding ligands related to the Notch pathway (1). Studies of the Notch signaling have flourished since then and the principal components and process of the signaling transduction cascade were identified. As a juxtacrine signaling, Notch signaling relies on the interaction between receptors and ligands expressed on juxtaposed cells to initiate signaling. The Notch signaling has been extensively characterized as a highly conserved pathway involved in cell proliferation, fate, differentiation, and stem cell maintenance (2). It is universally acknowledged that the normal Notch signaling is vital to most developmental decision-making in animals, and that pathway dysfunction is involved in many conditions, including cancer (3).

The Notch signaling pathway plays a critical role in tumor initiation and progression. Notch can function as an oncogene or a tumor suppressor in different cancers. Hypoxia is a common feature in a majority of malignant tumors. Hypoxia triggers a complex signaling network in tumor cells to alter cell metabolism and regulate angiogenesis, epithelia-mesenchymal transition (EMT), and the maintenance and functions of cancer stem cells (CSCs). Hypoxia-induced factors (HIFs), as global regulators of cellular hypoxia responses, can interact with Notch and directly regulate the Notch signaling pathway. This review systematically summarizes the intersection between Notch signaling and the cellular hypoxic response and highlights the underlying molecular mechanisms involved in the cancer pathogenesis, which contributes to the discovery and development of a combinational strategy targeting Notch and hypoxia in cancer treatment.

2 Notch signaling pathway

Notch signaling exerts its effect in a canonical or noncanonical fashion. The specific mechanisms of canonical and non-canonical Notch signaling are described as follows.

2.1 Canonical Notch signaling

Canonical Notch signaling is initiated by γ-secretase-mediated cleavage of the Notch receptor, resulting in the release of the active intracellular domain of Notch, which migrates to the nucleus and interacts with CSL (for CBF1, Suppressor of Hairless, Lag1; also known as RBPJ), leading to the activation of downstream target genes (Figure 1). In mammals, there are four Notch receptors (Notch 1/2/3/4) and five ligands (Delta-like 1/3/4 or Jagged 1/2). The Notch receptors and ligands are structurally related in some ways. They both contain a large number of epidermal growth factor (EGF)-like repeats in their extracellular domains. Briefly, Notch receptors are produced in the endoplasmic reticulum and synthesized as single precursor proteins, which are then trafficked to the Golgi compartment. In the Golgi compartment, Notch receptor precursors undergo S1 cleavage by a furin-like protease, creating the heterodimeric Notch receptor consisting of a Notch extracellular domain (NECD) and a Notch transmembrane and intracellular domain (TMIC). The part of the extracellular domain of Notch receptor consists of 36 EGF-like repeats and a negative regulatory region. EGF-like repeats 11 and 12 function as specific protein binding domains mediating interaction with ligands (4). The ligand-receptor interaction triggers proteolytic cleavages by an ADAM metalloprotease (S2-cleavage). In this process, ligand will be endocytosed after it binds to Notch receptor. Epsin-dependent ligand endocytosis exerts force on the negative regulatory region exposing the S2 site for cleavage (5). Then, the remainder of the receptor subjected to S3 cleavage by the γ-secretase complex releases the Notch intracellular domain (NICD), which translocates into the nucleus. In the nucleus, NICD interacts with a DNA-binding protein CSL, converting CSL from a transcriptional repressor to an activator. The NICD-CSL interaction is stabilized by Mastermind like transcriptional coactivator (MAML), forming a ternary NICD/MAML/CSL complex to activate the transcription of downstream genes including Hes (hairy-enhancer of split), Hey (Hes related to YRPW), and so on (6, 7). Different ligands could generate diverse Notch activity dynamics in signaling receiving cells, inducing different cell fates via activating distinct target gene programs (8).

Figure 1

2.2 Non-canonical Notch signaling

Non-canonical Notch signaling is an important arm of Notch signaling. Notch is proved active in cells where the canonical ligands and downstream effectors were defective, indicating that Notch acts in a second way independently (9). Non-canonical Notch signaling can be initiated by a non-canonical ligand via CSL-independent manner (10–12).

Notch signaling can be elicited by diverse non-canonical ligands, including ligands structurally similar to canonical ligands, structurally unrelated ligands, and secreted proteins (13, 14). Delta like non-canonical Notch ligand 1 is an integral membrane protein containing tandem EGF-like repeats in its extracellular domain but lacking the DSL domain. It can directly interact with Notch1 and act as an antagonist (14). Another structurally similar non-canonical ligand Delta/Notch-like EGF-related receptor functioned as a trans-ligand to affect glial morphological changes (15). A diverse group of structurally unrelated non-canonical ligands have also been identified as Notch activators. F3/contactin1 and NB3/contactin6 interacted with Notch EGF-like repeat distal to the DSL domain binding site to induce oligodendrocyte differentiation (11, 16). In addition, a number of secreted proteins act as non-canonical ligands of Notch. In vertebrates, CCN3 and MAGP-2 can bind to the extracellular domains of Notch receptor, resulting in its cleavage and activation (17, 18). In Drosophila, Scabrous activated transcription of the Notch target gene E(spl)C m3 to regulate eye ommatidia and sensory bristles (19, 20).

In CSL-independent non-canonical Notch signaling, the cleaved NICD interacts with multiple pathways and regulates cell survival. The CSL knockout mice developed breast tumors similar to CSL heterozygous and control mice, indicating that Notch-induced breast tumor development was CSL-independent (21). Interleukin-6 has been identified as a novel Notch target in breast tumor cells. The Notch-mediated interleukin-6 up-regulation required two NF-κB signaling-related proteins and P53 (22). The membrane-tethered NICD inhibited cell apoptosis through interacting with mTOR and Rictor (companion of mTOR) to trigger Akt phosphorylation in activated T cells (23). Notch activated the PI3K-Akt pathway via Deltex1 and played oncogenic functions in cervical cancer (24). In addition, Notch1 was demonstrated to directly regulate vascular barrier function through a flow-mediated, non-canonical, transcription-independent signaling mechanism (25, 26).

3 Notch signaling pathway in cancer

The mutations in the Notch signaling pathway genes and dysregulated Notch signaling pathways exhibit dual biological functions in tumorigenesis and cancer progression (Table 1). Notch1 mutation was first identified in patients with acute T-cell acute lymphoblastic leukemia (T-ALL) and occurs in approximately 50% of T-ALL (27). Oncogenic and gain-­of-­function mutations of Notch genes have been implicated in chronic lymphocytic leukemia (30), splenic marginal zone B-cell lymphoma (31), squamous cell lung carcinoma (44) and salivary adenoid cystic carcinomas (58). Moreover, aberrant activation of Notch signaling has been found in many solid tumors including prostate (59), breast (60), cervical (61), melanoma (62), and lung cancer (63, 64).

Table 1

Tumor TypeOncogenic or Tumor SuppressiveMutations
Acute lymphoblastic T-cell leukemiaOncogenicNotch1 (27), Notch3 (28), FBXW7 (29)
Chronic lymphocytic leukemiaOncogenicNotch1 (30)
Splenic marginal zone lymphomaOncogenicNotch2 (31)
Diffuse large cell B lymphomaOncogenicNotch1 (32), Notch2 (33)
Adenoid cystic carcinomaOncogenicNotch1, Notch2 (34, 35)
Breast cancerOncogenicNotch1, Notch2 (36)
Infantile myofibromatosisOncogenicNotch3 (37)
Glomus tumorsOncogenicNotch1, Notch2, Notch3 (38)
Head and neck squamous cell carcinomasTumor SuppressiveNotch1 (39, 40)
Small cell lung cancersTumor SuppressiveNotch1, Notch2, Notch3, Notch4 (41)
Bladder cancerTumor SuppressiveNotch1, Notch2, Notch3, MAML (42, 43)
Cutaneous and lung squamous cell carcinomaTumor SuppressiveNotch1, Notch2 (44)
Cholangiocellular carcinomaOncogenicNo mutations (45)
Hepatocellular carcinomaOncogenic and Tumor SuppressiveNo mutations (46–48)
Pancreatic ductal adenocarcinomaOncogenic and Tumor SuppressiveNo mutations (49, 50)
MelanomaOncogenicNo mutations (51, 52)
Prostate cancerOncogenicNo mutations (53, 54)
GlioblastomaOncogenicNo mutations (55–57)

The Oncogenic and tumor suppressive roles of Notch signaling in human cancers.

MAML, Mastermind like transcriptional coactivator.

In addition, Notch signaling can interact with other signaling pathways to promote tumorigenesis and cancer progression (Table 2). The Notch signaling contributed to the development of leukemia and breast cancer through interacting with the NF-κB pathway (22, 65, 82). Notch inhibited cervical cancer cell apoptosis via the mTOR–Rictor pathway (23).

Table 2

Interaction with other pathwaysTumor Type
NF-κB pathwayLeukemic T cells (65), prostate cancer (66), breast cancer (22)
PI3K/Akt pathwayCervical cancer (24), melanoma (67), breast cancer (68), lung adenocarcinoma (69)
Wnt/β-catenin pathwayColorectal cancer (70)
HIF pathwayPancreatic cancer (71), breast cancer (72), glioblastoma (73)
MAPK pathwayMelanoma (67), thyroid papillary cancer (74), breast cancer (75), head and neck squamous cell carcinoma (76)
TGF-β/smad pathwayBreast cancer (77), clear cell renal cell carcinoma (78)
mTOR pathwayCervical cancer (23)
P53 pathwayLung adenocarcinoma (79), keratinocyte cancer (80), T-cell lymphoma (81)

The cross-talk between Notch signaling and other pathways in cancers.

In addition to its oncogenic role in human malignancies, Notch also functions as a tumor suppressor (83). Nicolas et al. has demonstrated that Notch1 deficiency in skin resulted in the sustained expression of Gli2 and derepressed β-catenin signaling, causing the development of tumor (84). In addition, Notch was reported to play a suppressive role in B cell ALL (85), human hepatocellular carcinoma (86), small cell lung cancer (41), and neuroendocrine tumors (87). In a word, Notch acts as an oncogene or tumor suppressor in cancer depending on different contexts. To comprehend the full spectrum of Notch effects, efforts were required to identify the specific ligand-receptor interactions, the downstream targets of Notch signaling, and the functions of Notch modifiers (88).

Tumor microenvironment is comprised of a complex network, including stromal cells, immune cells, fibroblasts, blood vessels, and secreted factors (89). The interaction between tumor cells and tumor microenvironment (TME) is interdependent. A normal TME has a potential to suppress tumors. Lim et al. has suggested that tumor-stroma interactions can drive disease progression in squamous cell carcinoma arising in different tissues, indicating that the tumor context defines metastatic progression (90).

Accumulating evidence suggested that Notch signaling plays a role in regulating the immune responses in tumors, which may be associated with the critical role of Notch signaling in hematopoiesis and immune development (88, 91). A single-cell RNA-sequencing analysis has revealed that Jagged1-Notch pathway regulated immune cell homeostasis during minimal residual disease in hematologic neoplasm, which was a potential target to delay tumor recurrence (92). In breast cancer, the Jagged1-Notch pathway regulated tumor-associated macrophage differentiation towards M2 phenotype to induce aromatase inhibitor resistance (93). Activation of the Notch signaling in triple-negative breast cancer resulted in the secretion of pro-inflammatory cytokines and the recruitment of pro-tumoral macrophages to the TME (94). Delta-like 1 (Dll1)-mediated Notch signaling was implicated in the crosstalk between tumor cells and cancer-associated fibroblasts to promote radio-resistance in breast cancer (95). In general, Notch signaling plays a critical role in regulating tumor cells and TME, which may provide new strategies for Notch-targeted cancer therapy.

4 Hypoxia in cancer

Oxygen is indispensable for mammals that maintain intracellular ATP levels and serves as an electron acceptor in a large number of biochemical reactions (96). Hypoxia is a major feature of solid tumor and associated with poor prognosis and resistance to therapy (97–99). Under hypoxic condition, tumor cells undergo various biological processes including cell proliferation, migration, apoptosis, and EMT (100). Hypoxia also triggers multiple signaling pathways to regulate advanced but dysfunctional vascularization in TME (101).

The transcriptional factor HIFs are principal regulators and orchestrate cellular adaptive mechanisms in responses to hypoxia. HIFs contain two different subunits: α and β. The α-subunit protein is regulated by cellular oxygen levels, whereas the β subunit is constitutively expressed (102, 103). HIF-α proteins are oxygen-sensitive that contain an oxygen-dependent degradation domain with target prolyl residues, and a C-terminal transactivation domain which contains the target asparaginyl residue. Under normoxic condition, HIF-α subunits are hydroxylated by prolyl hydroxylases. After hydroxylation, the von-Hippel Lindau tumor suppressor gene interacts with HIF-α and tags it for 26s proteasomal degradation (104, 105). Under hypoxic condition, HIF-α hydroxylation is prevented due to the inactivation of prolyl hydroxylases, resulting in the inhibition of ubiquitin-mediated proteasome degradation of HIF-α. HIF-α is stabilized and form the HIF heterodimer, which then enters the nucleus and combines with hypoxia-response elements to activate the downstream genes (106). Moreover, HIF transcriptional activity is modulated by factor inhibiting HIF-1 (FIH-1), which hydroxylates an asparagine residue in the transactivation domain of HIF-α subunits, thereby blocking its transactivation function (107, 108).

There are three known α subunits (HIF-1α, HIF-2α, and HIF-3α) and three β subunits (HIF-1β, HIF-2β, and HIF-3β). HIF-1α is widely expressed in most human tissues, while HIF-2α and HIF-3α are detected in more restricted tissues, such as lung, kidney, and so on (109, 110). In canonical HIF signaling, hypoxia leads to the stabilization of the labile protein HIF-1α or HIF-2α which complexes with HIF-β, forming heterodimers that bind to hypoxia-response elements in target genes (111). HIF-1α and HIF-2α are structurally closely related and share both common and distinct target genes (112). The role of HIF-3α in the regulation of the HIF pathway is not completely understood and mainly regarded as a negative regulator of HIF-1α and HIF-2α (113).

HIFs are overexpressed and significantly associated with poor prognosis in a variety of cancers (114–117). HIFs-regulated genes encode proteins involved in critical aspects of cancer biology, including energy metabolism, cell survival and invasion, angiogenesis, EMT, and so on. Tumor cells tend to turn metabolism from an oxygen-dependent tricarboxylic acid cycle to glycolysis (118). HIF-1 regulates glycolytic enzymes, including hexokinase 2 and phosphofructokinase 1, which involved in tumor initiation and growth (119, 120). A number of growth factors regulated by HIFs played a role in cell survival, such as transforming growth factor-β, insulin-like growth factor 2, endothelin-1, erythropoietin, and epidermal growth factor receptor (100, 121–123). HIFs mediated angiogenesis via activating the transcription of multiple angiogenic growth factors, including vascular endothelial growth factor (VEGF), placenta-like growth factor, angiopoietin (124, 125). HIF-1 can directly induces the transcription of ZEB1, TWIST, and TCF3, which promote EMT in cancers (126–128). In a word, HIFs play a key role in cancer initiation and progression.

5 Crosstalk between Notch signaling and hypoxia pathway

HIF signaling pathway is the primary regulator in the physiological and pathological response to hypoxia. The Notch signaling pathway plays a critical role in cell fate control, including tumorigenesis and progression. The link between Notch signaling and hypoxia was first described in a transcriptomic analysis, in which the Notch target gene Hes1 was upregulated in hypoxic neuroblastoma cell lines (129). Thereafter, a study of Notch and hypoxia-activated genes in glioblastoma tumor confirmed a combined gene signature of these two pathways and their role in tumor prognosis (130). Gustaffson et al. provided important evidence that hypoxia directly regulated Notch signaling (131). In this study, HIF-1α was recruited to Notch-responsive promoters and interacted with NICD, leading to stabilization of NICD and activation of Notch downstream genes (Hes and Hey). HIF-1α can also be recruited to the Hey-2 promoter in myogenic cell (131). The up-regulation of the Notch ligands (Jagged 2 and Delta-like 4) induced by hypoxia leaded to activation of Notch signaling (132–134). HIF-2α promoted stem phenotype conversion and resistance to Paclitaxel by activating Notch and Wnt pathways in breast cancer cells (72). Besides, HIF-1α was revealed to interact with γ-secretase and upregulate γ-secretase activity to promote cell invasion and metastasis through a novel function independent of transcription factor (135). HIF-1α and HIF-2α synergized with the Notch co-activator MAML1 to potentiate Notch activity in breast cancer cells (136). The indirect regulation of Notch signaling by HIF was reported in lung cancer cells that HIF-mediated miR-1275 up-regulation exerted its tumorigenic effect through co-activating Notch and Wnt/β-catenin signaling pathways (137).

On the other hand, Notch signaling can also regulate hypoxic response. Notch was demonstrated to transcriptionally upregulate the expression of HIF-2α in certain tumor cells via a HIF1α-to-HIF2α switch (138). The γ-secretase inhibitor of Notch decreased the mRNA expression of the HIF-1 target PGK-1 (131).

FIH-1 is involved in the crosstalk between hypoxia and Notch signaling pathways. Both HIF-1α and Notch are substrates for the asparagine hydroxylase FIH-1. Two asparagine residues in the NICD ankyrin repeat domain are hydroxylated by FIH-1, leading to inactivation of Notch signaling. FIH-1 binds to NICD more efficiently than HIF-1α, indicating that NICD sequesters FIH-1 away from HIF-1α, which results in an under-hydroxylation on HIF1α (139, 140). This may shed light on another oxygen-dependent interface that modulates HIF signaling.

To summarize, the crosstalk between Notch signaling and the cellular hypoxic response is extensive and the underlying molecular mechanism is complex (Figure 2). A Notch-hypoxia crosstalk has been involved in a variety of physiological situations and pathological conditions, including vascular diseases and cancers (64, 141).

Figure 2

6 Biological processes in cancer regulated by a Notch-hypoxia crosstalk

A functional relationship between hypoxia and Notch signaling pathways has been observed in many types of tumors. Accumulating evidences have revealed that the crosstalk between Notch and the cellular hypoxic response has diverse roles in cancer pathogenesis by regulating several important biological processes, including EMT, angiogenesis, the maintenance of CSCs, and so on.

6.1 A Notch-hypoxia crosstalk in cancer EMT

EMT is one of the critical mechanisms of cancer metastasis (142, 143). The hallmark of EMT is the loss of E-cadherin expression through the up-regulation of its repressors (144, 145). E-cadherin repressors are classified into two groups depending on their effects on the E-cadherin promoter. Snail, Zeb, E47, and KLF8 bind to and repress the activity of the E-cadherin promoter (146, 147), whereas several factors such as Twist, Goosecoid, E2.2, and FoxC2 indirectly repress E-cadherin transcription (148).

HIF-1 was reported to upregulate the expression of Twist to promote EMT (149). A number of studies suggested that hypoxia induced EMT via activating Notch signaling in tumor cells (136, 150–152). Notch can regulate the expression of Snail-1 via two distinct mechanisms in hypoxia. One relied on the transcriptional up-regulation of Snail-1. The other concerned the protein stabilization of Snail-1 via the increase of lysyl oxidase which was transcriptionally regulated by HIF-1α and potentiated by Notch (150). Hypoxia-mediated increase in Snail and Slug required Notch pathway in the initiation of EMT in breast cancer cells (136). HIF-1α can also exert a non-transcriptional function in regulating the expression of NICD and E-cadherin in lung cancer cells (153).

6.2 A Notch-hypoxia crosstalk in angiogenesis

Tumor growth is fed by nearby blood vessels. Hypoxia occurs as the tumor grows. New blood vessels are essential for continued primary tumor growth. The ability of forming vasculature has been termed angiogenesis. Activation of endothelial cells was a key step of angiogenesis and a number of growth factors upregulated by HIF were involved in the process, such as VEGF (154).

Notch signaling was activated and played an important role in the process of angiogenesis (155). The expression of Notch ligand Dll4 was much higher in the endothelium of tumor blood vessels compared to nearby normal blood vessels, indicating that Notch signaling were implicated in tumor angiogenesis (132, 156, 157). Dll4 was upregulated by VEGF as a negative feedback modulator, which prevented VEGF-induced overexuberant angiogenic sprouting and branching via Notch signaling, guaranteeing the formation of a well-differentiated vascular network (158, 159). HIF­1α-induced basic fibroblast growth factor and VEGF were reported to play a synergistic role in the regulation of Dll4 in tumor cells (156). Hypoxia-induced up-regulation of Dll4 and Hey repressed COUP-TFII (known as a regulator of vein identity) in endothelial progenitor cells, which may contribute to tumor angiogenesis (160). Another Notch ligand Jagged 2 was transcriptionally activated by HIF-1α, which triggered Notch signaling and activated Hey1 to promote vascular development and angiogenesis (133).

6.3 A Notch-hypoxia crosstalk in the maintenance of CSCs

CSCs represent a discrete subpopulation of cancer cells with stem cell properties, which is responsible for tumor growth. CSCs are self-renewal and can produce more committed progenitor or “transit-amplifying” cells whose progeny differentiate aberrantly to promote the tumorigenesis (161, 162). Stem cell “niches” are considered as particular microenvironments that maintain the combined properties of CSCs self-renewal and multipotency. The Notch signaling is highly conserved and is critical for cell fate decisions and the maintenance of stem cells (163). HIF stabilization in hypoxic tumor cells can promote stem cell properties, including self-renewal and multipotency partly via inducing the expression and activity of the Notch signaling pathway (164–167). Hypoxia-induced the 66-kDa isoform of the SHC gene controlled the expression of Notch3 to regulate the stem cell properties (168). In glioblastomas, HIF-1α played an important role in the hypoxia-mediated maintenance of glioma stem cells via the interaction with NICD (73). A further study suggested that hypoxia can promote glioma stem cells proliferation and maintain the characteristics of stem cells through activating Notch1 and Oct3/4 (169). In addition, HIF-1α was reported to promote pancreatic cancer cell dedifferentiation into stem-like cell phenotypes by activating Notch signaling, revealing a novel regulatory mechanism (71).

7 Strategies for cancer therapy

7.1 Therapeutic targets in the Notch signaling pathway

In view of the critical role of Notch signaling in tumor pathogenesis, Notch is regarded as a promising therapeutic target. Numerous approaches have been developed to inhibit different steps of Notch signaling pathway for therapy: γ-secretase inhibitors (GSIs), antibodies targeting ligands or receptors, compounds targeting transcription activation, and so on (Figure 3). The drugs are listed by therapeutic category in Table 3.

Figure 3

Table 3

ClassTargetTumor type
GSIsγ-secretaseT-cell acute lymphoblastic leukemia (170), breast cancer (171), lung adenocarcinoma (172), colorectal cancer (173), prostate cancer (174)
Transcription blockerCSL/NICD complexHematologic cancer (175), breast cancer (176)
Antibodies against Notch receptorsNotch1T-acute lymphoblastic leukemia (177), adenoid cystic carcinoma (178)
Notch2/Notch3Untreated metastatic pancreatic cancer (179), small cell lung cancer (180), and other solid tumors (181)
Notch3Advanced breast cancer and other solid tumors (182)
Antibodies against Notch ligandsJagged-1Breast cancer (183), and other malignant tumors (184)
Delta-like ligand 3Small cell lung cancer (185)
Delta-like ligand 4Ovarian cancer (186), Metastatic non-squamous non-small cell lung cancer (187), and other advanced solid tumors (188)
Enhance Notch signaling activationNotch negative regulatory regionAcute myeloid leukemia (189)
Therapeutic non-coding RNAsMiRNAsProstate cancer (190), breast cancer (191), ovarian cancer (192), pancreatic cancer (193)
LncRNAsOvarian cancer (194), nasopharyngeal carcinoma (195)

Therapeutic approaches targeting Notch signaling pathway.

GSIs=γ-secretase inhibitors; miRNAs=microRNAs; lncRNAs=long non-coding RNAs.

GSIs were the first and most extensively studied small-molecule Notch inhibitors. Initially, GSIs were developed for treating Alzheimer’s disease because γ-secretase catalyzed the production of the β-amyloid peptide from amyloid precursor protein (196). The use of GSIs for cancer treatment is based on inhibiting the cleavage of γ-secretase which mediates S3 cleavage to generate NICD, resulting in blocking Notch signaling. However, studies have shown that systemic inhibition of Notch signaling by GSIs results in “on-target” gastrointestinal toxicity because of the accumulation of secretory goblet cells in the intestine. The above observation can be explained by alterations in the differentiation of intestinal stem cells following the dual inhibition of Notch1 and Notch2 (197). Co-administration of glucocorticoid may alleviate the toxicity through inducing transcriptional up-regulation of cyclin D2 and protecting mice from developing the GSIs-induced intestinal goblet cell metaplasia in a preclinical mouse model of T-ALL (198).

Considering the inherent mechanism-based toxicity caused by pan-Notch inhibitor GSIs, novel inhibitors that selectively target individual Notch ligands and receptors have been developed. Selective blocking of Notch1 signaling inhibited cancer cell growth and deregulation of angiogenesis (199). The antibodies against Notch receptors are divided into two classes, one directed against the EGF-like repeat region and the other directed against the Notch negative regulatory region (200). Several potent and selective inhibitors against Notch1, Notch2, and Notch3 have been developed (199, 201, 202). However, there is a lack of inhibitor against Notch 4. The antibodies that selectively target the canonical ligands have also been investigated, such as Jagged antagonism (203).

In the past decades, several molecules targeting Notch trafficking and processing have been developed. The dihydropyridine FLI-06 as the first small molecular chemical compound functioned at an early stage in secretory traffic through disrupting the Golgi apparatus and inhibiting general secretion before exiting from the endoplasmic reticulum (204). FLI-06 was also demonstrated to block Notch activation and decrease the self-renewal ability of tongue CSCs (205). In addition, direct inhibition of the CSL/NICD complex has been reported to treat cancers. SAHM1, as a high-affinity binding of the hydrocarbon-stapled peptide, could prevent the assembly of the active transcriptional complex, resulting in genome-wide suppression of Notch-activated genes for the treatment of leukemia (206). There are other small molecules inhibiting the transcriptional activation complex, which have been investigated, such as IMR-1, CB-103, and RIN1 (175, 176, 207). However, given that loss of CSL derepressed target gene promoter and promoted tumorigenesis, targeting CSL may bring potential problems (208).

As mentioned above, Notch can act as a tumor suppressor in specific contexts, thus enhancing Notch signaling activation is a potential therapeutic strategy for cancer. A study demonstrated that N-methylhemeanthidine chloride, a novel Amaryllidaceae alkaloid, activated the Notch signaling via docking in the hydrophobic cavity within the Notch1 negative regulatory region and promoting Notch1 proteolytic cleavage (189). A monoclonal antibody was reported to enhance Notch3 cleavage and mimic the effects of ligand-induced Notch activation via binding to overlapping epitopes within negative regulatory region (202).

Accumulating evidence demonstrated that the non-coding RNAs’ (ncRNAs) played a critical role in cancer therapy. NcRNAs are a class of RNAs including microRNAs (miRNAs) and long ncRNAs (lncRNAs) and other short ncRNAs. miRNAs and lncRNAs regulated cell fate determination via various signaling pathways (209). miRNA-34 was reported to suppress Notch1 expression, inducing ovarian cancer cell death (210). In contrast, miRNA-223 as an oncogene activated Notch signaling to induce tumor cell proliferation in colorectal cancer (211). The versatility is one of the advantages of miRNA therapeutics, which can suppress or mimic the activity of a miRNA. However, the delivery of miRNA remains an important challenge. LncRNAs mostly act as oncogenes in cancers. LncRNAs can interact with Notch or act as competing endogenous RNAs for miRNAs to indirectly induce Notch signaling in various cancers (212–214). Besides, other therapeutics targeting Notch are currently under investigation, such as natural products, virotherapy, and so on.

7.2 Hypoxia targeting strategies

Considering the critical role of hypoxia in tumor initiation, progression and therapy resistance, a growing number of preclinical and clinical cancer studies targeting hypoxia have been performed. In general, the strategies can be classified into hypoxia activated prodrugs (HAPs) and pharmacological inhibitors of the HIF signaling pathway.

7.2.1 Hypoxia activated prodrugs

HAPs are bioreductive drugs which are reduced by specific reductases under hypoxic conditions and release cytotoxins to kill cells (215). Five different chemical entities have the potential to target hypoxia based on their enzymatical reductive reaction under hypoxic conditions (216), including nitro groups, quinones, aromatic N-oxides, aliphatic N-oxides and transition metals. To date, several HAPs have been developed, including EO9 (apaziquone), RH1, SR 4233 (tirapazamine), SN30000, AQ4N (banoxantrone), PR-104, and TH-302 (evofosfamide) (Table 4). The effects of HAPs are different depending on the degree of hypoxia and the activity of reductase enzymes. The selection of the appropriate agents in different patients is dependent on the clinical context and requires predictive biomarkers (225).

Table 4

ClassProdrugCurrent statusTumor type
QuinoneE09 (Apaziquone)IIIBladder cancer (217)
RH1ISolid tumors (218)
Aromatic N-oxideSR 4233 (Tirapazamine)IIINon-small-cell lung cancer (219)
SN30000PreclinicalTriple-negative breast cancer (220)
Aliphatic N-oxideAQ4N (Banoxantrone)ISolid tumors (221, 222)
NitroPR-104IIAcute myeloid leukemia/lymphoblastic leukemia (223)
TH-302 (Evofosfamide)IIISoft-tissue sarcomas (224)

Hypoxia-activated prodrugs in clinical development.

7.2.2 Inhibitors of HIF signaling

HIF signaling is an attractive target for cancer treatment. Several inhibitors have been developed to directly bind to HIF-1α or HIF-2α, resulting in inhibition of their heterodimerization with HIF-β, such as acriflavine (226), PT2385 (227) and PT2399 (228). Heat shock protein 90 (Hsp90) can bind to HIF-1α and block the VHL-dependent proteasomal degradation of HIF-1α. A number of Hsp90 inhibitors have been developed during the past two decades. Hsp90 was identified as the biological target of the ansamycin class of natural products and derivatives, which has been extensively studied in cancer treatment (229). Hsp90 inhibitors apigenin and radicicol reduced hypoxia-induced VEGF expression to decrease angiogenesis (230, 231). Hsp90 can also modulate the conformation of the HIF-1 heterodimer, increasing its interaction with hypoxia-responsive elements, inducing HIF-1 transcriptional activity (231). Hsp90 can be regulated by posttranslational modifications, including acetylation. The process of histone acetylation is regulated by opposing activities of histone acetyltransferases and histone deacetylases (HDACs). HDAC6 functions as an Hsp90 deacetylase (232). HDAC inhibitor vorinostat was developed to inhibit HIF-1 transcriptional activity via direct Hsp90 acetylation, decreasing Hsp90-HIF-1 affinity and the interaction between HIF and hypoxia-responsive elements (233). Chetomin, a small molecule blocking the transcriptional co-activation of HIF-1 pathway, was evaluated as a promising candidate treatment for several types of cancers (234). Paradoxically, the stabilization of HIF-1α through inhibition of prolyl hydroxylase domain-containing protein 2 has antitumor effects in certain context. The loss of EGLN1 which encodes prolyl hydroxylase domain-containing protein 2 inhibited the proliferation of clear cell ovarian cancer cells (235). In general, anti-HIF agents are classified by different molecular mechanisms, including inhibition of HIF protein synthesis, degradation, and transcriptional activity. A detailed review of experimental chemical compounds and approved drugs directly targeting HIF pathway are presented in Table 5.

Table 5

Mechanism of inhibitionCompound/drug nameCurrent statusTumor type
Inhibit HIF-1α mRNA expressionEZN-2698IAdvanced malignancies (236)
Inhibit HIF-1α protein expressionDigoxinIIBiochemically relapsed prostate cancer (237)
2-methoxyestradiolIIMultiple types of cancer (238)
PX-478IAdvanced solid tumors and lymphomas (239)
Increased HIF-1α degradationYC-1PreclinicalSeveral solid tumors (240)
PX-12IIPreviously treated advanced pancreatic cancer (241)
LW6PreclinicalColon cancer (242)
Inhibit HIF heterodimerizationAcriflavinPreclinicalProstate cancer (226)
PT-2385IAdvanced clear cell renal cell carcinoma (243)
PT-2399PreclinicalpVHL-defective clear cell renal cell carcinoma (244)
Inhibit HIF-1/DNA bindingEchinomycinIISeveral advanced cancers (245–249)
Inhibit HIF-1 transcriptional activityChetominPreclinicalMultiple myeloma (250)
BortezomibFDA approvedMultiple myeloma and several solid tumors (251)
VorinostatIIMetastatic urothelial cancer (252)

Inhibitors directly targeting the HIF pathway in cancers.

Targeting HIF signaling can be performed via interfering with other signaling pathways. PI3K/AKT/mTOR and MAPK/ERK pathways can increase HIF-1α synthesis in a cell type-specific manner (253). PI3K inhibitors LY294002 and wortmannin have been recognized as the synthesis inhibition of HIF-1α protein in the prostate carcinoma-derived cell lines PC-3 and DU145 (254). Temsirolimus, everolimus, and sirolimus as mTOR inhibitors are currently in clinical development for the treatment of solid tumors (255). The phase III clinical trials for temsirolimus and everolimus have been completed and showed a significant gain in survival for patients of metastatic renal cell carcinoma (256).

7.3 Combination therapy

Combination therapy is an important trend in the development of anticancer agents, and targeting hypoxia is critical in the new strategy (225). The anti-hypoxia agents were combined with immune checkpoint inhibitors to enhance the effect of immune checkpoint inhibitors in cancer treatment, which was based on hypoxia-induced expression and activity of immune checkpoints and immune checkpoint ligands on immune-cells and tumor cells (257). A phase II clinical trial of pembrolizumab and HDAC inhibitor vorinostat demonstrated the combination was active for patients with recurrent/metastatic squamous cell carcinomas of the head and neck, and salivary gland cancer (258). In a neuroblastoma xenograft model, the combination of anti-angiogenic drug sunitinib with hypoxia-activated prodrug evofosfamide was demonstrated to improve survival of mice (259).

Hypoxia and cellular interaction between tumor and non-tumor cells are two important TME. There are strong links between these two themes, and hypoxia contributes to TME to adversely affect therapeutic outcomes. Notch signaling plays an important role in regulating the crosstalk between the different compartments of the TME. Therefore, a combination of targeting Notch and hypoxia implies a potential treatment strategy of cancer to alter TME. In addition, hypoxia and Notch signaling have been shown to form a complex web of interaction in cancer, providing new insights into the combination therapeutics. Notch is a key regulator of tumor angiogenesis (260). The anti-angiogenesis drugs aggravated tumor hypoxia (261), indicating that targeting Notch may induce hypoxia. While, hypoxia activated Notch signaling pathway and may reduce the effect of Notch signaling inhibitors. Therefore, the combination of anti-hypoxia and Notch-targeted agents may present a new strategy for addressing the adverse effect of hypoxia.

8 Conclusion

The Notch signaling, as an evolutionarily conserved pathway, is usually activated and extensively involved in tumor initiation and progression. Notch signaling plays a critical role in the interaction between the tumor cells and the surrounding TME, acting as an oncogene or a tumor suppressor. Hypoxia is recognized as a hallmark of TME and the HIF pathway is a master regulator of the cellular hypoxic response. The interaction of Notch and HIF pathways played a key role in multiple biological processes in hypoxic tumor, including EMT, angiogenesis, and the maintenance of CSCs. A broad spectrum of anti-hypoxia agents and Notch signaling inhibitors have been developed during the past decades. The combination therapy has been an important trend of cancer treatment. Considering the complex web of hypoxia and Notch signaling, the combination of them implies a potential treatment strategy of cancer.

Statements

Author contributions

XCL and MG conceived the study. MG drafted the manuscript. XCL revised the manuscript critically for important intellectual content. YN, MX, and XSL provided important comments on the manuscript. All authors approved the final version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors contributed to the article and approved the submitted version. The reviewer BZ declared a shared affiliation with the authors to the handling editor at the time of review.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

HIFs, Hypoxia-induced factors; EMT, Epithelial-mesenchymal transition; CSCs, Cancer stem cells; EGF, Epidermal growth factor; NICD, Notch intracellular domain; MAML, Mastermind like transcriptional coactivator; ALL, Acute lymphoblastic leukemia; TME, Tumor microenvironment; FIH-1, Factor inhibiting HIF-1; VEGF, Vascular endothelial growth factor; Dll4, Delta-like 4; GSIs, γ-secretase inhibitors; NcRNAs, Non-coding RNAs; MiRNAs, MicroRNAs; LncRNAs, Long non-coding RNAs; HAPs, Hypoxia activated prodrugs; Hsp90, Heat shock protein 90; HDACs, Histone deacetylases.

References

  • 1

    MugishaSDiXDisomaCJiangHZhangS. Fringe family genes and their modulation of notch signaling in cancer. Biochim Biophys Acta Rev Cancer (2022) 1877(4):188746. doi: 10.1016/j.bbcan.2022.188746

  • 2

    SiebelCLendahlU. Notch signaling in development, tissue homeostasis, and disease. Physiol Rev (2017) 97(4):1235–94. doi: 10.1152/physrev.00005.2017

  • 3

    Artavanis-TsakonasSMuskavitchMA. Notch: the past, the present, and the future. Curr Top Dev Biol (2010) 92:1–29. doi: 10.1016/s0070-2153(10)92001-2

  • 4

    RebayIFlemingRJFehonRGCherbasLCherbasPArtavanis-TsakonasS. Specific EGF repeats of notch mediate interactions with delta and serrate: implications for notch as a multifunctional receptor. Cell (1991) 67(4):687–99. doi: 10.1016/0092-8674(91)90064-6

  • 5

    LangridgePDStruhlG. Epsin-dependent ligand endocytosis activates notch by force. Cell (2017) 171(6):1383–96.e12. doi: 10.1016/j.cell.2017.10.048

  • 6

    BraySJ. Notch signalling in context. Nat Rev Mol Cell Biol (2016) 17(11):722–35. doi: 10.1038/nrm.2016.94

  • 7

    SprinzakDBlacklowSC. Biophysics of notch signaling. Annu Rev Biophys (2021) 50:157–89. doi: 10.1146/annurev-biophys-101920-082204

  • 8

    NandagopalNSantatLALeBonLSprinzakDBronnerMEElowitzMB. Dynamic ligand discrimination in the notch signaling pathway. Cell (2018) 172(4):869–80.e19. doi: 10.1016/j.cell.2018.01.002

  • 9

    RusconiJCCorbinV. Evidence for a novel notch pathway required for muscle precursor selection in drosophila. Mech Dev (1998) 79(1-2):39–50. doi: 10.1016/s0925-4773(98)00170-1

  • 10

    AyazFOsborneBA. Non-canonical notch signaling in cancer and immunity. Front Oncol (2014) 4:345. doi: 10.3389/fonc.2014.00345

  • 11

    HuQDAngBTKarsakMHuWPCuiXYDukaTet al. F3/contactin acts as a functional ligand for notch during oligodendrocyte maturation. Cell (2003) 115(2):163–75. doi: 10.1016/s0092-8674(03)00810-9

  • 12

    ShinHMMinterLMChoOHGottipatiSFauqAHGoldeTEet al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J (2006) 25(1):129–38. doi: 10.1038/sj.emboj.7600902

  • 13

    D'SouzaBMiyamotoAWeinmasterG. The many facets of notch ligands. Oncogene (2008) 27(38):5148–67. doi: 10.1038/onc.2008.229

  • 14

    TraustadóttirGJensenCHThomassenMBeckHCMortensenSBLabordaJet al. Evidence of non-canonical NOTCH signaling: Delta-like 1 homolog (DLK1) directly interacts with the NOTCH1 receptor in mammals. Cell Signal (2016) 28(4):246–54. doi: 10.1016/j.cellsig.2016.01.003

  • 15

    EirakuMTohgoAOnoKKanekoMFujishimaKHiranoTet al. DNER acts as a neuron-specific notch ligand during bergmann glial development. Nat Neurosci (2005) 8(7):873–80. doi: 10.1038/nn1492

  • 16

    CuiXYHuQDTekayaMShimodaYAngBTNieDYet al. NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes. J Biol Chem (2004) 279(24):25858–65. doi: 10.1074/jbc.M313505200

  • 17

    HeathETahriDAndermarcherESchofieldPFlemingSBoulterCA. Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol (2008) 8:18. doi: 10.1186/1471-213x-8-18

  • 18

    MiyamotoALauRHeinPWShipleyJMWeinmasterG. Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation. J Biol Chem (2006) 281(15):10089–97. doi: 10.1074/jbc.M600298200

  • 19

    BakerNEMlodzikMRubinGM. Spacing differentiation in the developing drosophila eye: a fibrinogen-related lateral inhibitor encoded by scabrous. Science (1990) 250(4986):1370–7. doi: 10.1126/science.2175046

  • 20

    PowellPAWesleyCSpencerSCaganRL. Scabrous complexes with notch to mediate boundary formation. Nature (2001) 409(6820):626–30. doi: 10.1038/35054566

  • 21

    RaafatALawsonSBargoSKlauzinskaMStrizziLGoldharASet al. Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis. Oncogene (2009) 28(2):219–30. doi: 10.1038/onc.2008.379

  • 22

    JinSMutveiAPChivukulaIVAnderssonERRamsköldDSandbergRet al. Non-canonical notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene (2013) 32(41):4892–902. doi: 10.1038/onc.2012.517

  • 23

    PerumalsamyLRNagalaMBanerjeePSarinA. A hierarchical cascade activated by non-canonical notch signaling and the mTOR-rictor complex regulates neglect-induced death in mammalian cells. Cell Death Differ (2009) 16(6):879–89. doi: 10.1038/cdd.2009.20

  • 24

    VeeraraghavaluKSubbaiahVKSrivastavaSChakrabartiOSyalRKrishnaS. Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J Virol (2005) 79(12):7889–98. doi: 10.1128/jvi.79.12.7889-7898.2005

  • 25

    PolacheckWJKutysMLYangJEyckmansJWuYVasavadaHet al. A non-canonical notch complex regulates adherens junctions and vascular barrier function. Nature (2017) 552(7684):258–62. doi: 10.1038/nature24998

  • 26

    FischerABragaVMM. Vascular permeability: Flow-mediated, non-canonical notch signalling promotes barrier integrity. Curr Biol (2018) 28(3):R119–r121. doi: 10.1016/j.cub.2017.11.065

  • 27

    WengAPFerrandoAALeeWJPtMLBSSanchez-IrizarryCet al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269–71. doi: 10.1126/science.1102160

  • 28

    Bernasconi-EliasPHuTJenkinsDFirestoneBGansSKurthEet al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene (2016) 35(47):6077–86. doi: 10.1038/onc.2016.133

  • 29

    KingBTrimarchiTReavieLXuLMullendersJNtziachristosPet al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 153(7):1552–66. doi: 10.1016/j.cell.2013.05.041

  • 30

    FabbriGRasiSRossiDTrifonovVKhiabanianHMaJet al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 208(7):1389–401. doi: 10.1084/jem.20110921

  • 31

    KielMJVelusamyTBetzBLZhaoLWeigelinHGChiangMYet al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 209(9):1553–65. doi: 10.1084/jem.20120910

  • 32

    LohrJGStojanovPLawrenceMSAuclairDChapuyBSougnezCet al. Discovery and prioritization of somatic mutations in diffuse large b-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U.S.A. (2012) 109(10):3879–84. doi: 10.1073/pnas.1121343109

  • 33

    LeeSYKumanoKNakazakiKSanadaMMatsumotoAYamamotoGet al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large b-cell lymphoma. Cancer Sci (2009) 100(5):920–6. doi: 10.1111/j.1349-7006.2009.01130.x

  • 34

    XieMWeiSWuXLiXYouYHeC. Alterations of notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. Lung Cancer (2018) 121:41–7. doi: 10.1016/j.lungcan.2018.04.020

  • 35

    StephensPJDaviesHRMitaniYVan LooPShlienATarpeyPSet al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest (2013) 123(7):2965–8. doi: 10.1172/jci67201

  • 36

    PappasKMartinTCWolfeALNguyenCBSuTJinJet al. NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Commun Biol (2021) 4(1):312. doi: 10.1038/s42003-021-01825-8

  • 37

    WuDWangSOliveiraDVDel GaudioFVanlandewijckMLebouvierTet al. The infantile myofibromatosis NOTCH3 L1519P mutation leads to hyperactivated ligand-independent notch signaling and increased PDGFRB expression. Dis Model Mech (2021) 14(2):dmm046300. doi: 10.1242/dmm.046300

  • 38

    MosqueraJMSbonerAZhangLChenCLSungYSChenHWet al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer (2013) 52(11):1075–87. doi: 10.1002/gcc.22102

  • 39

    AgrawalNFrederickMJPickeringCRBettegowdaCChangKLiRJet al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 333(6046):1154–7. doi: 10.1126/science.1206923

  • 40

    StranskyNEgloffAMTwardADKosticADCibulskisKSivachenkoAet al. The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 333(6046):1157–60. doi: 10.1126/science.1208130

  • 41

    GeorgeJLimJSJangSJCunYOzretićLKongGet al. Comprehensive genomic profiles of small cell lung cancer. Nature (2015) 524(7563):47–53. doi: 10.1038/nature14664

  • 42

    MaraverAFernandez-MarcosPJCashTPMendez-PertuzMDueñasMMaiettaPet al. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest (2015) 125(2):824–30. doi: 10.1172/jci78185

  • 43

    RampiasTVgenopoulouPAvgerisMPolyzosAStravodimosKValavanisCet al. A new tumor suppressor role for the notch pathway in bladder cancer. Nat Med (2014) 20(10):1199–205. doi: 10.1038/nm.3678

  • 44

    WangNJSanbornZArnettKLBaystonLJLiaoWProbyCMet al. Loss-of-function mutations in notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U.S.A. (2011) 108(43):17761–6. doi: 10.1073/pnas.1114669108

  • 45

    ZenderSNickeleitIWuestefeldTSörensenIDauchDBozkoPet al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell (2013) 23(6):784–95. doi: 10.1016/j.ccr.2013.04.019

  • 46

    GramantieriLGiovanniniCLanziAChiecoPRavaioliMVenturiAet al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int (2007) 27(7):997–1007. doi: 10.1111/j.1478-3231.2007.01544.x

  • 47

    NingLWentworthLChenHWeberSM. Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res (2009) 1(4):358–66.

  • 48

    QiRAnHYuYZhangMLiuSXuHet al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res (2003) 63(23):8323–9.

  • 49

    YeJWenJNingYLiY. Higher notch expression implies poor survival in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Pancreatology (2018) 18(8):954–61. doi: 10.1016/j.pan.2018.09.014

  • 50

    HanlonLAvilaJLDemarestRMTroutmanSAllenMRattiFet al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res (2010) 70(11):4280–6. doi: 10.1158/0008-5472.Can-09-4645

  • 51

    BalintKXiaoMPinnixCCSomaAVeresIJuhaszIet al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 115(11):3166–76. doi: 10.1172/JCI25001

  • 52

    MüllerCS. Notch signaling and malignant melanoma. Adv Exp Med Biol (2012) 727:258–64. doi: 10.1007/978-1-4614-0899-4_19

  • 53

    ZhangLShaJYangGHuangXBoJHuangY. Activation of notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells. Cell Cycle (2017) 16(10):999–1007. doi: 10.1080/15384101.2017.1312237

  • 54

    ZhuHZhouXRedfieldSLewinJMieleL. Elevated jagged-1 and notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res (2013) 5(3):368–78.

  • 55

    BazzoniRBentivegnaA. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel) (2019) 11(3):292. doi: 10.3390/cancers11030292

  • 56

    El HindyNKeyvaniKPagenstecherADammannPSandalciogluIESureUet al. Implications of Dll4-notch signaling activation in primary glioblastoma multiforme. Neuro Oncol (2013) 15(10):1366–78. doi: 10.1093/neuonc/not071

  • 57

    PurowBWHaqueRMNoelMWSuQBurdickMJLeeJet al. Expression of notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 65(6):2353–63. doi: 10.1158/0008-5472.Can-04-1890

  • 58

    HoASOchoaAJayakumaranGZehirAValero MayorCTepeJet al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest (2019) 129(10):4276–89. doi: 10.1172/jci128227

  • 59

    SantagataSDemichelisFRivaAVaramballySHoferMDKutokJLet al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64(19):6854–7. doi: 10.1158/0008-5472.Can-04-2500

  • 60

    ReedijkMOdorcicSChangLZhangHMillerNMcCreadyDRet al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 65(18):8530–7. doi: 10.1158/0008-5472.CAN-05-1069

  • 61

    ZagourasPStifaniSBlaumuellerCMCarcangiuMLArtavanis-TsakonasS. Alterations in notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U.S.A. (1995) 92(14):6414–8. doi: 10.1073/pnas.92.14.6414

  • 62

    HendrixMJSeftorRESeftorEAGrumanLMLeeLMNickoloffBJet al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res (2002) 62(3):665–8.

  • 63

    ChenYDe MarcoMAGrazianiIGazdarAFStrackPRMieleLet al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res (2007) 67(17):7954–9. doi: 10.1158/0008-5472.Can-07-1229

  • 64

    LiXCaoXZhaoHGuoMFangXLiKet al. Hypoxia activates Notch4 via ERK/JNK/P38 MAPK signaling pathways to promote lung adenocarcinoma progression and metastasis. Front Cell Dev Biol (2021) 9:780121. doi: 10.3389/fcell.2021.780121

  • 65

    VaccaAFelliMPPalermoRDi MarioGCalceADi GiovineMet al. Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J (2006) 25(5):1000–8. doi: 10.1038/sj.emboj.7600996

  • 66

    ZhangJKuangYWangYXuQRenQ. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-κB pathway. Apoptosis (2017) 22(6):877–84. doi: 10.1007/s10495-017-1368-0

  • 67

    LiuZJXiaoMBalintKSmalleyKSBraffordPQiuRet al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating n-cadherin expression. Cancer Res (2006) 66(8):4182–90. doi: 10.1158/0008-5472.Can-05-3589

  • 68

    LiXWangSDengNGuoXFuMMaYet al. N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide induces apoptosis in human breast cancer cells by stimulating oxidative stress and inhibiting the notch-akt signaling pathway. Oxid Med Cell Longev (2022) 2022:8123120. doi: 10.1155/2022/8123120

  • 69

    WangWSunRZengLChenYZhangNCaoSet al. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma. Life Sci (2021) 276:119439. doi: 10.1016/j.lfs.2021.119439

  • 70

    CampsJPittJJEmonsGHummonABCaseCMGradeMet al. Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer. Cancer Res (2013) 73(6):2003–13. doi: 10.1158/0008-5472.Can-12-3159

  • 71

    MuRZouYKTuKWangDBTangDYuZet al. Hypoxia promotes pancreatic cancer cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential by the HIF-1α/Notch signaling pathway. Pancreas (2021) 50(5):756–65. doi: 10.1097/mpa.0000000000001828

  • 72

    YanYLiuFHanLZhaoLChenJOlopadeOIet al. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating wnt and notch pathways. J Exp Clin Cancer Res (2018) 37(1):256. doi: 10.1186/s13046-018-0925-x

  • 73

    QiangLWuTZhangHWLuNHuRWangYJet al. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating notch signaling pathway. Cell Death Differ (2012) 19(2):284–94. doi: 10.1038/cdd.2011.95

  • 74

    YamashitaASGeraldoMVFuziwaraCSKulcsarMAFrigugliettiCUda CostaRBet al. Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer proliferation. Transl Oncol (2013) 6(2):197–205. doi: 10.1593/tlo.12442

  • 75

    IzrailitJBermanHKDattiAWranaJLReedijkM. High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental notch regulators in breast cancer. Proc Natl Acad Sci U.S.A. (2013) 110(5):1714–9. doi: 10.1073/pnas.1214014110

  • 76

    ZengQLiSChepehaDBGiordanoTJLiJZhangHet al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of notch signaling. Cancer Cell (2005) 8(1):13–23. doi: 10.1016/j.ccr.2005.06.004

  • 77

    SunYLowtherWKatoKBiancoCKenneyNStrizziLet al. Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling. Oncogene (2005) 24(34):5365–74. doi: 10.1038/sj.onc.1208528

  • 78

    SjölundJBoströmAKLindgrenDMannaSMoustakasALjungbergBet al. The notch and TGF-β signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One (2011) 6(8):e23057. doi: 10.1371/journal.pone.0023057

  • 79

    LicciulliSAvilaJLHanlonLTroutmanSCesaroniMKotaSet al. Notch1 is required for kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res (2013) 73(19):5974–84. doi: 10.1158/0008-5472.Can-13-1384

  • 80

    LefortKMandinovaAOstanoPKolevVCalpiniVKolfschotenIet al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev (2007) 21(5):562–77. doi: 10.1101/gad.1484707

  • 81

    BeverlyLJFelsherDWCapobiancoAJ. Suppression of p53 by notch in lymphomagenesis: implications for initiation and regression. Cancer Res (2005) 65(16):7159–68. doi: 10.1158/0008-5472.Can-05-1664

  • 82

    ShinHMTilahunMEChoOHChandiranKKuksinCAKeerthivasanSet al. NOTCH1 can initiate NF-κB activation via cytosolic interactions with components of the T cell signalosome. Front Immunol (2014) 5:249. doi: 10.3389/fimmu.2014.00249

  • 83

    MaillardIPearWS. Notch and cancer: best to avoid the ups and downs. Cancer Cell (2003) 3(3):203–5. doi: 10.1016/s1535-6108(03)00052-7

  • 84

    NicolasMWolferARajKKummerJAMillPvan NoortMet al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet (2003) 33(3):416–21. doi: 10.1038/ng1099

  • 85

    Zweidler-McKayPAHeYXuLRodriguezCGKarnellFGCarpenterACet al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of b-cell malignancies. Blood (2005) 106(12):3898–906. doi: 10.1182/blood-2005-01-0355

  • 86

    ViatourPEhmerUSaddicLADorrellCAndersenJBLinCet al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 208(10):1963–76. doi: 10.1084/jem.20110198

  • 87

    CrabtreeJSSingletonCSMieleL. Notch signaling in neuroendocrine tumors. Front Oncol (2016) 6:94. doi: 10.3389/fonc.2016.00094

  • 88

    MaillardIAdlerSHPearWS. Notch and the immune system. Immunity (2003) 19(6):781–91. doi: 10.1016/s1074-7613(03)00325-x

  • 89

    CaseySCAmedeiAAquilanoKAzmiASBenenciaFBhaktaDet al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 35 Suppl(Suppl):S199–s223. doi: 10.1016/j.semcancer.2015.02.007

  • 90

    LimYZSouthAP. Tumour-stroma crosstalk in the development of squamous cell carcinoma. Int J Biochem Cell Biol (2014) 53:450–8. doi: 10.1016/j.biocel.2014.06.012

  • 91

    MaillardIHeYPearWS. From the yolk sac to the spleen: New roles for notch in regulating hematopoiesis. Immunity (2003) 18(5):587–9. doi: 10.1016/s1074-7613(03)00119-5

  • 92

    JanghorbanMYangYZhaoNHamorCNguyenTMZhangXHet al. Single-cell analysis unveils the role of the tumor immune microenvironment and notch signaling in dormant minimal residual disease. Cancer Res (2022) 82(5):885–99. doi: 10.1158/0008-5472.Can-21-1230

  • 93

    LiuHWangJZhangMXuanQWangZLianXet al. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients. Breast Cancer Res Treat (2017) 166(1):95–107. doi: 10.1007/s10549-017-4394-2

  • 94

    JaiswalAMurakamiKEliaAShibaharaYDoneSJWoodSAet al. Therapeutic inhibition of USP9x-mediated notch signaling in triple-negative breast cancer. Proc Natl Acad Sci U.S.A. (2021) 118(38):e2101592118. doi: 10.1073/pnas.2101592118

  • 95

    NandiADebnathRNayakAToTKJThackerGReillyMet al. Dll1-mediated notch signaling drives tumor cell cross-talk with cancer-associated fibroblasts to promote radioresistance in breast cancer. Cancer Res (2022) 82(20):3718–33. doi: 10.1158/0008-5472.Can-21-1225

  • 96

    LeePChandelNSSimonMC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol (2020) 21(5):268–83. doi: 10.1038/s41580-020-0227-y

  • 97

    VaupelPMayerA. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 26(2):225–39. doi: 10.1007/s10555-007-9055-1

  • 98

    Brahimi-HornMCChicheJPouysségurJ. Hypoxia and cancer. J Mol Med (Berl) (2007) 85(12):1301–7. doi: 10.1007/s00109-007-0281-3

  • 99

    QiuGZJinMZDaiJXSunWFengJHJinWL. Reprogramming of the tumor in the hypoxic niche: The emerging concept and associated therapeutic strategies. Trends Pharmacol Sci (2017) 38(8):669–86. doi: 10.1016/j.tips.2017.05.002

  • 100

    HarrisAL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 2(1):38–47. doi: 10.1038/nrc704

  • 101

    MuzBde la PuentePAzabFAzabAK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) (2015) 3:83–92. doi: 10.2147/hp.S93413

  • 102

    SemenzaGL. Hypoxia-inducible factors in physiology and medicine. Cell (2012) 148(3):399–408. doi: 10.1016/j.cell.2012.01.021

  • 103

    KaelinWGJr.RatcliffePJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 30(4):393–402. doi: 10.1016/j.molcel.2008.04.009

  • 104

    JaakkolaPMoleDRTianYMWilsonMIGielbertJGaskellSJet al. Targeting of HIF-alpha to the von hippel-lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 292(5516):468–72. doi: 10.1126/science.1059796

  • 105

    CockmanMEMassonNMoleDRJaakkolaPChangGWCliffordSCet al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von hippel-lindau tumor suppressor protein. J Biol Chem (2000) 275(33):25733–41. doi: 10.1074/jbc.M002740200

  • 106

    WuDPotluriNLuJKimYRastinejadF. Structural integration in hypoxia-inducible factors. Nature (2015) 524(7565):303–8. doi: 10.1038/nature14883

  • 107

    MahonPCHirotaKSemenzaGL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev (2001) 15(20):2675–86. doi: 10.1101/gad.924501

  • 108

    LandoDPeetDJGormanJJWhelanDAWhitelawMLBruickRK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev (2002) 16(12):1466–71. doi: 10.1101/gad.991402

  • 109

    YangSLWuCXiongZFFangX. Progress on hypoxia-inducible factor-3: Its structure, gene regulation and biological function (Review). Mol Med Rep (2015) 12(2):2411–6. doi: 10.3892/mmr.2015.3689

  • 110

    TalksKLTurleyHGatterKCMaxwellPHPughCWRatcliffePJet al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 157(2):411–21. doi: 10.1016/s0002-9440(10)64554-3

  • 111

    SuzukiNGradinKPoellingerLYamamotoM. Regulation of hypoxia-inducible gene expression after HIF activation. Exp Cell Res (2017) 356(2):182–6. doi: 10.1016/j.yexcr.2017.03.013

  • 112

    KennethNSRochaS. Regulation of gene expression by hypoxia. Biochem J (2008) 414(1):19–29. doi: 10.1042/bj20081055

  • 113

    HeikkiläMPasanenAKivirikkoKIMyllyharjuJ. Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell Mol Life Sci (2011) 68(23):3885–901. doi: 10.1007/s00018-011-0679-5

  • 114

    FrolovaOSamudioIBenitoJMJacamoRKornblauSMMarkovicAet al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther (2012) 13(10):858–70. doi: 10.4161/cbt.20838

  • 115

    DalesJPGarciaSMeunier-CarpentierSAndrac-MeyerLHaddadOLavautMNet al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer (2005) 116(5):734–9. doi: 10.1002/ijc.20984

  • 116

    RasheedSHarrisALTekkisPPTurleyHSilverAMcDonaldPJet al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer (2009) 100(10):1666–73. doi: 10.1038/sj.bjc.6605026

  • 117

    SchmitzKJMüllerCIReisHAlakusHWindeGBabaHAet al. Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. Int J Colorectal Dis (2009) 24(11):1287–96. doi: 10.1007/s00384-009-0753-8

  • 118

    Vander HeidenMGCantleyLCThompsonCB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324(5930):1029–33. doi: 10.1126/science.1160809

  • 119

    WolfAAgnihotriSMicallefJMukherjeeJSabhaNCairnsRet al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med (2011) 208(2):313–26. doi: 10.1084/jem.20101470

  • 120

    YiWClarkPMMasonDEKeenanMCHillCGoddardWA3rd. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 337(6097):975–80. doi: 10.1126/science.1222278

  • 121

    MaxwellPHPughCWRatcliffePJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev (2001) 11(3):293–9. doi: 10.1016/s0959-437x(00)00193-3

  • 122

    GrimshawMJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer (2007) 14(2):233–44. doi: 10.1677/erc-07-0057

  • 123

    SmithKGunaratnamLMorleyMFranovicAMekhailKLeeS. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res (2005) 65(12):5221–30. doi: 10.1158/0008-5472.Can-05-0169

  • 124

    ReySSemenzaGL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res (2010) 86(2):236–42. doi: 10.1093/cvr/cvq045

  • 125

    KellyBDHackettSFHirotaKOshimaYCaiZBerg-DixonSet al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 93(11):1074–81. doi: 10.1161/01.Res.0000102937.50486.1b

  • 126

    ZhangWShiXPengYWuMZhangPXieRet al. HIF-1α promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS One (2015) 10(6):e0129603. doi: 10.1371/journal.pone.0129603

  • 127

    YangMHWuMZChiouSHChenPMChangSYLiuCJet al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol (2008) 10(3):295–305. doi: 10.1038/ncb1691

  • 128

    KrishnamacharyBZagzagDNagasawaHRaineyKOkuyamaHBaekJHet al. Hypoxia-inducible factor-1-dependent repression of e-cadherin in von hippel-lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 66(5):2725–31. doi: 10.1158/0008-5472.Can-05-3719

  • 129

    JögiAØraINilssonHLindeheimAMakinoYPoellingerLet al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U.S.A. (2002) 99(10):7021–6. doi: 10.1073/pnas.102660199

  • 130

    IrshadKMohapatraSKSrivastavaCGargHMishraSDikshitBet al. A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLoS One (2015) 10(3):e0118201. doi: 10.1371/journal.pone.0118201

  • 131

    GustafssonMVZhengXPereiraTGradinKJinSLundkvistJet al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell (2005) 9(5):617–28. doi: 10.1016/j.devcel.2005.09.010

  • 132

    MailhosCModlichULewisJHarrisABicknellRIsh-HorowiczD. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation (2001) 69(2-3):135–44. doi: 10.1046/j.1432-0436.2001.690207.x

  • 133

    PietrasAvon StedingkKLindgrenDPåhlmanSAxelsonH. JAG2 induction in hypoxic tumor cells alters notch signaling and enhances endothelial cell tube formation. Mol Cancer Res (2011) 9(5):626–36. doi: 10.1158/1541-7786.Mcr-10-0508

  • 134

    LannerFLeeKLOrtegaGCSohlMLiXJinSet al. Hypoxia-induced arterial differentiation requires adrenomedullin and notch signaling. Stem Cells Dev (2013) 22(9):1360–9. doi: 10.1089/scd.2012.0259

  • 135

    VillaJCChiuDBrandesAHEscorciaFEVillaCHMaguireWFet al. Nontranscriptional role of hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell Rep (2014) 8(4):1077–92. doi: 10.1016/j.celrep.2014.07.028

  • 136

    ChenJImanakaNChenJGriffinJD. Hypoxia potentiates notch signaling in breast cancer leading to decreased e-cadherin expression and increased cell migration and invasion. Br J Cancer (2010) 102(2):351–60. doi: 10.1038/sj.bjc.6605486

  • 137

    JiangNZouCZhuYLuoYChenLLeiYet al. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating wnt/β-catenin and notch signaling. Theranostics (2020) 10(6):2553–70. doi: 10.7150/thno.41120

  • 138

    MutveiAPLandorSKFoxRBrauneEBTsoiYLPhoonYPet al. Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types. Oncogene (2018) 37(46):6083–95. doi: 10.1038/s41388-018-0400-3

  • 139

    ColemanMLMcDonoughMAHewitsonKSColesCMecinovicJEdelmannMet al. Asparaginyl hydroxylation of the notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem (2007) 282(33):24027–38. doi: 10.1074/jbc.M704102200

  • 140

    ZhengXLinkeSDiasJMZhengXGradinKWallisTPet al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the notch and hypoxia signaling pathways. Proc Natl Acad Sci U.S.A. (2008) 105(9):3368–73. doi: 10.1073/pnas.0711591105

  • 141

    GuoMZhangMCaoXFangXLiKQinLet al. Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension. Respir Res (2022) 23(1):6. doi: 10.1186/s12931-022-01927-9

  • 142

    DongreAWeinbergRA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol (2019) 20(2):69–84. doi: 10.1038/s41580-018-0080-4

  • 143

    LinYTWuKJ. Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling. J BioMed Sci (2020) 27(1):39. doi: 10.1186/s12929-020-00632-3

  • 144

    WellsAYatesCShepardCR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis (2008) 25(6):621–8. doi: 10.1007/s10585-008-9167-1

  • 145

    SchmalhoferOBrabletzSBrabletzT. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 28(1-2):151–66. doi: 10.1007/s10555-008-9179-y

  • 146

    PeinadoHOlmedaDCanoA. Snail, zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 7(6):415–28. doi: 10.1038/nrc2131

  • 147

    WangXZhengMLiuGXiaWMcKeown-LongoPJHungMCet al. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res (2007) 67(15):7184–93. doi: 10.1158/0008-5472.Can-06-4729

  • 148

    SobradoVRMoreno-BuenoGCubilloEHoltLJNietoMAPortilloFet al. The class I bHLH factors E2-2A and E2-2B regulate EMT. J Cell Sci (2009) 122(Pt 7):1014–24. doi: 10.1242/jcs.028241

  • 149

    YangMHWuKJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle (2008) 7(14):2090–6. doi: 10.4161/cc.7.14.6324

  • 150

    SahlgrenCGustafssonMVJinSPoellingerLLendahlU. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U.S.A. (2008) 105(17):6392–7. doi: 10.1073/pnas.0802047105

  • 151

    IshidaTHijiokaHKumeKMiyawakiANakamuraN. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett (2013) 6(5):1201–6. doi: 10.3892/ol.2013.1549

  • 152

    TianQXueYZhengWSunRJiWWangXet al. Overexpression of hypoxia-inducible factor 1α induces migration and invasion through notch signaling. Int J Oncol (2015) 47(2):728–38. doi: 10.3892/ijo.2015.3056

  • 153

    FujikiKInamuraHMiyayamaTMatsuokaM. Involvement of Notch1 signaling in malignant progression of A549 cells subjected to prolonged cadmium exposure. J Biol Chem (2017) 292(19):7942–53. doi: 10.1074/jbc.M116.759134

  • 154

    CookKMFiggWD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 60(4):222–43. doi: 10.3322/caac.20075

  • 155

    LiJLHarrisAL. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell (2005) 8(1):1–3. doi: 10.1016/j.ccr.2005.06.013

  • 156

    PatelNSLiJLGeneraliDPoulsomRCranstonDWHarrisAL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res (2005) 65(19):8690–7. doi: 10.1158/0008-5472.Can-05-1208

  • 157

    GaleNWDominguezMGNogueraIPanLHughesVValenzuelaDMet al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U.S.A. (2004) 101(45):15949–54. doi: 10.1073/pnas.0407290101

  • 158

    HainaudPContrerèsJOVillemainALiuLXPlouëtJTobelemGet al. The role of the vascular endothelial growth factor-delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res (2006) 66(17):8501–10. doi: 10.1158/0008-5472.Can-05-4226

  • 159

    HellströmMPhngLKHofmannJJWallgardECoultasLLindblomPet al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature (2007) 445(7129):776–80. doi: 10.1038/nature05571

  • 160

    DiezHFischerAWinklerAHuCJHatzopoulosAKBreierGet al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res (2007) 313(1):1–9. doi: 10.1016/j.yexcr.2006.09.009

  • 161

    HuntlyBJGillilandDG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer (2005) 5(4):311–21. doi: 10.1038/nrc1592

  • 162

    KeithBSimonMC. Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 129(3):465–72. doi: 10.1016/j.cell.2007.04.019

  • 163

    LiuJSatoCCerlettiMWagersA. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol (2010) 92:367–409. doi: 10.1016/s0070-2153(10)92012-7

  • 164

    WangKDingRHaYJiaYLiaoXWangSet al. Hypoxia-stressed cardiomyocytes promote early cardiac differentiation of cardiac stem cells through HIF-1α/Jagged1/Notch1 signaling. Acta Pharm Sin B (2018) 8(5):795–804. doi: 10.1016/j.apsb.2018.06.003

  • 165

    MainHLeeKLYangHHaapa-PaananenSEdgrenHJinSet al. Interactions between notch- and hypoxia-induced transcriptomes in embryonic stem cells. Exp Cell Res (2010) 316(9):1610–24. doi: 10.1016/j.yexcr.2009.12.012

  • 166

    MoriyamaHMoriyamaMIsshiHIshiharaSOkuraHIchinoseAet al. Role of notch signaling in the maintenance of human mesenchymal stem cells under hypoxic conditions. Stem Cells Dev (2014) 23(18):2211–24. doi: 10.1089/scd.2013.0642

  • 167

    ZhangSChanRWSNgEHYYeungWSB. Hypoxia regulates the self-renewal of endometrial mesenchymal Stromal/Stem-like cells via notch signaling. Int J Mol Sci (2022) 23(9):4613. doi: 10.3390/ijms23094613

  • 168

    SansonePStorciGGiovanniniCPandolfiSPianettiSTaffurelliMet al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells (2007) 25(3):807–15. doi: 10.1634/stemcells.2006-0442

  • 169

    ZengFChenHZhangZYaoTWangGZengQet al. Regulating glioma stem cells by hypoxia through the Notch1 and Oct3/4 signaling pathway. Oncol Lett (2018) 16(5):6315–22. doi: 10.3892/ol.2018.9442

  • 170

    PapayannidisCDeAngeloDJStockWHuangBShaikMNCesariRet al. A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J (2015) 5(9):e350. doi: 10.1038/bcj.2015.80

  • 171

    SardesaiSBadawiMMrozekEMorganEPhelpsMStephensJet al. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs (2020) 38(5):1400–10. doi: 10.1007/s10637-020-00895-5

  • 172

    MorganKMFischerBSLeeFYShahJJBertinoJRRosenfeldJet al. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther (2017) 16(12):2759–69. doi: 10.1158/1535-7163.Mct-17-0439

  • 173

    AkiyoshiTNakamuraMYanaiKNagaiSWadaJKogaKet al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology (2008) 134(1):131–44. doi: 10.1053/j.gastro.2007.10.008

  • 174

    CuiDDaiJKellerJMMizokamiAXiaSKellerET. Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin Cancer Res (2015) 21(20):4619–29. doi: 10.1158/1078-0432.Ccr-15-0242

  • 175

    HurtadoCSafarovaASmithMChungRBruyneelAANGomez-GalenoJet al. Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. Sci Rep (2019) 9(1):10811. doi: 10.1038/s41598-019-46948-5

  • 176

    LehalRZaricJVigoloMUrechCFrismantasVZanggerNet al. Pharmacological disruption of the notch transcription factor complex. Proc Natl Acad Sci U.S.A. (2020) 117(28):16292–301. doi: 10.1073/pnas.1922606117

  • 177

    AgnusdeiVMinuzzoSFrassonCGrassiAAxelrodFSatyalSet al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia (2014) 28(2):278–88. doi: 10.1038/leu.2013.183

  • 178

    FerrarottoREckhardtGPatnaikALoRussoPFaoroLHeymachJVet al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol (2018) 29(7):1561–8. doi: 10.1093/annonc/mdy171

  • 179

    HuZIBendellJCBullockALoConteNKHatoumHRitchPet al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med (2019) 8(11):5148–57. doi: 10.1002/cam4.2425

  • 180

    LuHJiangZ. Advances in antibody therapeutics targeting small-cell lung cancer. Adv Clin Exp Med (2018) 27(9):1317–23. doi: 10.17219/acem/70159

  • 181

    SmithDCChughRPatnaikAPapadopoulosKPWangMKapounAMet al. A phase 1 dose escalation and expansion study of tarextumab (OMP-59R5) in patients with solid tumors. Invest New Drugs (2019) 37(4):722–30. doi: 10.1007/s10637-018-0714-6

  • 182

    RosenLSWesolowskiRBaffaRLiaoKHHuaSYGibsonBLet al. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs (2020) 38(1):120–30. doi: 10.1007/s10637-019-00754-y

  • 183

    PandyaKWyattDGallagherBShahDBakerABloodworthJet al. PKCα attenuates jagged-1-Mediated notch signaling in ErbB-2-Positive breast cancer to reverse trastuzumab resistance. Clin Cancer Res (2016) 22(1):175–86. doi: 10.1158/1078-0432.Ccr-15-0179

  • 184

    MasieroMLiDWhitemanPBentleyCGreigJHassanaliTet al. Development of therapeutic anti-JAGGED1 antibodies for cancer therapy. Mol Cancer Ther (2019) 18(11):2030–42. doi: 10.1158/1535-7163.Mct-18-1176

  • 185

    SaundersLRBankovichAJAndersonWCAujayMABheddahSBlackKet al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med (2015) 7(302):302ra136. doi: 10.1126/scitranslmed.aac9459

  • 186

    Perez-FidalgoJAOrtegaBSimonSSamartzisEPBoussiosS. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med (2020) 8(24):1705. doi: 10.21037/atm-20-4497

  • 187

    McKeageMJKotasekDMarkmanBHidalgoMMillwardMJJamesonMBet al. Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC. Target Oncol (2018) 13(1):89–98. doi: 10.1007/s11523-017-0543-0

  • 188

    ChioreanEGLoRussoPStrotherRMDiamondJRYoungerAMessersmithWAet al. A phase I first-in-Human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin Cancer Res (2015) 21(12):2695–703. doi: 10.1158/1078-0432.Ccr-14-2797

  • 189

    YeQJiangJZhanGYanWHuangLHuYet al. Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia. Sci Rep (2016) 6:26510. doi: 10.1038/srep26510

  • 190

    Rios-ColonLChijiokeJNitureSAfzalZQiQSrivastavaAet al. Leptin modulated microRNA-628-5p targets jagged-1 and inhibits prostate cancer hallmarks. Sci Rep (2022) 12(1):10073. doi: 10.1038/s41598-022-13279-x

  • 191

    ParkEYChangELeeEJLeeHWKangHGChunKHet al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res (2014) 74(24):7573–82. doi: 10.1158/0008-5472.Can-14-1140

  • 192

    JeongJYKangHKimTHKimGHeoJHKwonAYet al. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett (2017) 386:168–78. doi: 10.1016/j.canlet.2016.11.017

  • 193

    ZhaoZShenXZhangDXiaoHKongHYangBet al. miR-153 enhances the therapeutic effect of radiotherapy by targeting JAG1 in pancreatic cancer cells. Oncol Lett (2021) 21(4):300. doi: 10.3892/ol.2021.12561

  • 194

    BaiLWangAZhangYXuXZhangX. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res (2018) 366(2):161–71. doi: 10.1016/j.yexcr.2018.03.014

  • 195

    ShenZWuYHeG. Long non-coding RNA PTPRG-AS1/microRNA-124-3p regulates radiosensitivity of nasopharyngeal carcinoma via the LIM homeobox 2-dependent notch pathway through competitive endogenous RNA mechanism. Bioengineered (2022) 13(4):8208–25. doi: 10.1080/21655979.2022.2037364

  • 196

    ImbimboBPPanzaFFrisardiVSolfrizziVD'OnofrioGLogroscinoGet al. Therapeutic intervention for alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs (2011) 20(3):325–41. doi: 10.1517/13543784.2011.550572

  • 197

    RiccioOvan GijnMEBezdekACPellegrinetLvan EsJHZimber-StroblUet al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008) 9(4):377–83. doi: 10.1038/embor.2008.7

  • 198

    RealPJToselloVPalomeroTCastilloMHernandoEde StanchinaEet al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2009) 15(1):50–8. doi: 10.1038/nm.1900

  • 199

    WuYCain-HomCChoyLHagenbeekTJde LeonGPChenYet al. Therapeutic antibody targeting of individual notch receptors. Nature (2010) 464(7291):1052–7. doi: 10.1038/nature08878

  • 200

    Aste-AmézagaMZhangNLinebergerJEArnoldBATonerTJGuMet al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One (2010) 5(2):e9094. doi: 10.1371/journal.pone.0009094

  • 201

    SharmaAGadkariRARamakanthSVPadmanabhanKMadhumathiDSDeviLet al. A novel monoclonal antibody against Notch1 targets leukemia-associated mutant Notch1 and depletes therapy resistant cancer stem cells in solid tumors. Sci Rep (2015) 5:11012. doi: 10.1038/srep11012

  • 202

    LiKLiYWuWGordonWRChangDWLuMet al. Modulation of notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem (2008) 283(12):8046–54. doi: 10.1074/jbc.M800170200

  • 203

    LafkasDSheltonAChiuCde Leon BoenigGChenYStawickiSSet al. Therapeutic antibodies reveal notch control of transdifferentiation in the adult lung. Nature (2015) 528(7580):127–31. doi: 10.1038/nature15715

  • 204

    KrämerAMentrupTKleizenBRivera-MillaEReichenbachDEnzenspergerCet al. Small molecules intercept notch signaling and the early secretory pathway. Nat Chem Biol (2013) 9(11):731–8. doi: 10.1038/nchembio.1356

  • 205

    GanRHLinLSXieJHuangLDingLCSuBHet al. FLI-06 intercepts notch signaling and suppresses the proliferation and self-renewal of tongue cancer cells. Onco Targets Ther (2019) 12:7663–74. doi: 10.2147/ott.S221231

  • 206

    MoelleringRECornejoMDavisTNDel BiancoCAsterJCBlacklowSCet al. Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 462(7270):182–8. doi: 10.1038/nature08543

  • 207

    AstudilloLDa SilvaTGWangZHanXJinKVanWyeJet al. The small molecule IMR-1 inhibits the notch transcriptional activation complex to suppress tumorigenesis. Cancer Res (2016) 76(12):3593–603. doi: 10.1158/0008-5472.Can-16-0061

  • 208

    KulicIRobertsonGChangLBakerJHLockwoodWWMokWet al. Loss of the notch effector RBPJ promotes tumorigenesis. J Exp Med (2015) 212(1):37–52. doi: 10.1084/jem.20121192

  • 209

    SlackFJChinnaiyanAM. The role of non-coding RNAs in oncology. Cell (2019) 179(5):1033–55. doi: 10.1016/j.cell.2019.10.017

  • 210

    JiaYLinRJinHSiLJianWYuQet al. MicroRNA-34 suppresses proliferation of human ovarian cancer cells by triggering autophagy and apoptosis and inhibits cell invasion by targeting notch 1. Biochimie (2019) 160:193–9. doi: 10.1016/j.biochi.2019.03.011

  • 211

    LiuZMaTDuanJLiuXLiuL. MicroRNA−223−induced inhibition of the FBXW7 gene affects the proliferation and apoptosis of colorectal cancer cells via the notch and Akt/mTOR pathways. Mol Med Rep (2021) 23(2):154. doi: 10.3892/mmr.2020.11793

  • 212

    PanTDingHJinLZhangSWuDPanWet al. DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway. Cell Cycle (2022) 21(21):2323–37. doi: 10.1080/15384101.2022.2094662

  • 213

    DengYZhangL. LncRNA SNHG11 accelerates the progression of lung adenocarcinoma via activating notch pathways. Pathol Res Pract (2022) 234:153849. doi: 10.1016/j.prp.2022.153849

  • 214

    JiangHLiXWangWDongH. Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway. BMC Cancer (2020) 20(1):838. doi: 10.1186/s12885-020-07275-5

  • 215

    PhillipsRM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol (2016) 77(3):441–57. doi: 10.1007/s00280-015-2920-7

  • 216

    WilsonWRHayMP. Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 11(6):393–410. doi: 10.1038/nrc3064

  • 217

    PhillipsRMLoadmanPMReddyG. Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. Cancer Chemother Pharmacol (2019) 83(6):1183–9. doi: 10.1007/s00280-019-03812-7

  • 218

    DansonSJJohnsonPWardTHDawsonMDennenyODickinsonGet al. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann Oncol (2011) 22(7):1653–60. doi: 10.1093/annonc/mdq638

  • 219

    WilliamsonSKCrowleyJJLaraPNJr.McCoyJLauDHTuckerRWet al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest oncology group trial S0003. J Clin Oncol (2005) 23(36):9097–104. doi: 10.1200/jco.2005.01.3771

  • 220

    HunterFWHsuHLSuJPullenSMWilsonWRWangJ. Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer. Mol Cancer Ther (2014) 13(11):2501–14. doi: 10.1158/1535-7163.Mct-14-0476

  • 221

    AlbertellaMRLoadmanPMJonesPHPhillipsRMRamplingRBurnetNet al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res (2008) 14(4):1096–104. doi: 10.1158/1078-0432.Ccr-07-4020

  • 222

    PapadopoulosKPGoelSBeeramMWongADesaiKHaigentzMet al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res (2008) 14(21):7110–5. doi: 10.1158/1078-0432.Ccr-08-0483

  • 223

    KonoplevaMThallPFYiCABorthakurGCovelerABueso-RamosCet al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica (2015) 100(7):927–34. doi: 10.3324/haematol.2014.118455

  • 224

    TapWDPapaiZVan TineBAAttiaSGanjooKNJonesRLet al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2017) 18(8):1089–103. doi: 10.1016/s1470-2045(17)30381-9

  • 225

    SingletonDCMacannAWilsonWR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol (2021) 18(12):751–72. doi: 10.1038/s41571-021-00539-4

  • 226

    LeeKZhangHQianDZReySLiuJOSemenzaGL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U.S.A. (2009) 106(42):17910–5. doi: 10.1073/pnas.0909353106

  • 227

    XieCGaoXSunDZhangYKrauszKWQinXet al. Metabolic profiling of the novel hypoxia-inducible factor 2α inhibitor PT2385 In vivo and in vitro. Drug Metab Dispos (2018) 46(4):336–45. doi: 10.1124/dmd.117.079723

  • 228

    ChenWHillHChristieAKimMSHollomanEPavia-JimenezAet al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature (2016) 539(7627):112–7. doi: 10.1038/nature19796

  • 229

    PorterJRGeJLeeJNormantEWestK. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Top Med Chem (2009) 9(15):1386–418. doi: 10.2174/156802609789895719

  • 230

    OsadaMImaokaSFunaeY. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett (2004) 575(1-3):59–63. doi: 10.1016/j.febslet.2004.08.036

  • 231

    HurEKimHHChoiSMKimJHYimSKwonHJet al. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol (2002) 62(5):975–82. doi: 10.1124/mol.62.5.975

  • 232

    KovacsJJMurphyPJGaillardSZhaoXWuJTNicchittaCVet al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 18(5):601–7. doi: 10.1016/j.molcel.2005.04.021

  • 233

    ZhangCYangCFeldmanMJWangHPangYMaggioDMet al. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget (2017) 8(34):56110–25. doi: 10.18632/oncotarget.18125

  • 234

    KungALZabludoffSDFranceDSFreedmanSJTannerEAVieiraAet al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 6(1):33–43. doi: 10.1016/j.ccr.2004.06.009

  • 235

    PriceCGillSHoZVDavidsonSMMerkelEMcFarlandJMet al. Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers. Cancer Res (2019) 79(10):2564–79. doi: 10.1158/0008-5472.Can-18-2674

  • 236

    GreenbergerLMHorakIDFilpulaDSapraPWestergaardMFrydenlundHFet al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther (2008) 7(11):3598–608. doi: 10.1158/1535-7163.Mct-08-0510

  • 237

    LinJZhanTDuffyDHoffman-CensitsJKilpatrickDTrabulsiEJet al. A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 2(1):21–32.

  • 238

    TinleyTLLealRMRandall-HlubekDACessacJWWilkensLRRaoPNet al. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res (2003) 63(7):1538–49.

  • 239

    LeeKKimHM. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res (2011) 34(10):1583–5. doi: 10.1007/s12272-011-1021-3

  • 240

    YeoEJChunYSChoYSKimJLeeJCKimMSet al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst (2003) 95(7):516–25. doi: 10.1093/jnci/95.7.516

  • 241

    RamanathanRKAbbruzzeseJDragovichTKirkpatrickLGuillenJMBakerAFet al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol (2011) 67(3):503–9. doi: 10.1007/s00280-010-1343-8

  • 242

    LeeKKangJEParkSKJinYChungKSKimHMet al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol (2010) 80(7):982–9. doi: 10.1016/j.bcp.2010.06.018

  • 243

    CourtneyKDInfanteJRLamETFiglinRARiniBIBrugarolasJet al. Phase I dose-escalation trial of PT2385, a first-in-Class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol (2018) 36(9):867–74. doi: 10.1200/jco.2017.74.2627

  • 244

    ChoHDuXRizziJPLiberzonEChakrabortyAAGaoWet al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature (2016) 539(7627):107–11. doi: 10.1038/nature19795

  • 245

    TaylorSAMetchBBalcerzakSPHansonKH. Phase II trial of echinomycin in advanced soft tissue sarcomas. a southwest oncology group study. Invest New Drugs (1990) 8(4):381–3. doi: 10.1007/bf00198595

  • 246

    BrownTDGoodmanPJFlemingTRTaylorSAMacdonaldJS. Phase II trial of echinomycin in advanced colorectal cancer. a southwest oncology group study. Invest New Drugs (1991) 9(1):113–4. doi: 10.1007/bf00194561

  • 247

    SchilskyRLFaraggiDKorzunAVogelzangNEllertonJWoodWet al. Phase II study of echinomycin in patients with advanced breast cancer: a report of cancer and leukemia group b protocol 8641. Invest New Drugs (1991) 9(3):269–72. doi: 10.1007/bf00176982

  • 248

    MarshallMEWolfMKCrawfordEDTaylorSBlumensteinBFlaniganRet al. Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. a southwest oncology group study. Invest New Drugs (1993) 11(2-3):207–9. doi: 10.1007/bf00874157

  • 249

    ShevrinDHLadTEGuinanPKiltonLJGreenburgAJohnsonPet al. Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. an Illinois cancer council study. Invest New Drugs (1994) 12(1):65–6. doi: 10.1007/bf00873239

  • 250

    ViziteuEGrandmouginCGoldschmidtHSeckingerAHoseDKleinBet al. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer (2016) 114(5):519–23. doi: 10.1038/bjc.2016.20

  • 251

    RichardsonPGMitsiadesCHideshimaTAndersonKC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 57:33–47. doi: 10.1146/annurev.med.57.042905.122625

  • 252

    QuinnDITsao-WeiDDTwardowskiPAparicioAMFrankelPChattaGet al. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide hydroxamic acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California cancer consortium trial, NCI 6879. Invest New Drugs (2021) 39(3):812–20. doi: 10.1007/s10637-020-01038-6

  • 253

    AlbadariNDengSLiW. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discovery (2019) 14(7):667–82. doi: 10.1080/17460441.2019.1613370

  • 254

    JiangBHJiangGZhengJZLuZHunterTVogtPK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ (2001) 12(7):363–9.

  • 255

    WangDEisenHJ. Mechanistic target of rapamycin (mTOR) inhibitors. Handb Exp Pharmacol (2022) 272:53–72. doi: 10.1007/164_2021_553

  • 256

    RavaudABernhardJCGross-GoupilMDigueLFerriereJM. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. Bull Cancer (2010) 97:45–51. doi: 10.1684/bdc.2010.1069

  • 257

    KopeckaJSalaroglioICPerez-RuizESarmento-RibeiroABSaponaraSDe Las RivasJet al. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Update (2021) 59:100787. doi: 10.1016/j.drup.2021.100787

  • 258

    RodriguezCPWuQVVoutsinasJFrommJRJiangXPillarisettyVGet al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res (2020) 26(4):837–45. doi: 10.1158/1078-0432.Ccr-19-2214

  • 259

    KumarSSunJDZhangLMokhtariRBWuBMengFet al. Hypoxia-targeting drug evofosfamide (TH-302) enhances sunitinib activity in neuroblastoma xenograft models. Transl Oncol (2018) 11(4):911–9. doi: 10.1016/j.tranon.2018.05.004

  • 260

    AkilAGutiérrez-GarcíaAKGuenterRRoseJBBeckAWChenHet al. Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: An update and prospective. Front Cell Dev Biol (2021) 9:642352. doi: 10.3389/fcell.2021.642352

  • 261

    HuHChenYTanSWuSHuangYFuSet al. The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol (2022) 13:802846. doi: 10.3389/fimmu.2022.802846

Summary

Keywords

Notch signaling, hypoxia, hypoxia-induced factors pathway, cancer, therapeutics

Citation

Guo M, Niu Y, Xie M, Liu X and Li X (2023) Notch signaling, hypoxia, and cancer. Front. Oncol. 13:1078768. doi: 10.3389/fonc.2023.1078768

Received

24 October 2022

Accepted

19 January 2023

Published

31 January 2023

Volume

13 - 2023

Edited by

João Pessoa, University of Coimbra, Portugal

Reviewed by

Binghan Zhou, Huazhong University of Science and Technology, China; Olivier Meurette, Université Claude Bernard Lyon 1, France; Xiawa Mao, Zhejiang University, China

Updates

Copyright

© 2023 Guo, Niu, Xie, Liu and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xiaochen Li,

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics